Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters
Author:
Affiliation:
1. Astellas Pharma Inc. Northbrook Illinois USA
2. PMSI Republican Clinical Hospital “Timofei, Moşneaga,” ARENSIA EM Chişinău Moldova
3. Pfizer Inc. San Diego California USA
Funder
Pfizer
Publisher
Wiley
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13229
Reference33 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2. Polypharmacy in elderly patients with cancer: clinical implications and management
3. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010
4. Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
5. Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Repurposing cardiac glycosides for anticancer treatment: a review of clinical studies;Drug Discovery Today;2024-10
2. Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments;Critical Reviews in Oncology/Hematology;2024-08
3. Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy;Drug Safety;2024-04-12
4. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates;Journal of Pharmacokinetics and Pharmacodynamics;2023-06-21
5. Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information;Cardiovascular Drugs and Therapy;2023-05-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3